To the Editor: The report of the ABOARD trial by Dr Montalescot and colleagues1 provided important information on the feasibility of an early invasive diagnostic strategy in patients with non–ST-segment elevation acute coronary syndromes (NSTE-ACS). However, the influence of timing of the therapeutic intervention, especially percutaneous coronary intervention (PCI), might be more subtle than ABOARD could evaluate. In ABOARD, only 222 of 352 patients (63%) were treated with PCI. Because of a wide diversity in patient characteristics, such as time from onset of pain and treatment modalities, firm conclusions cannot be drawn for PCI use.
Riezebos RK, Laarman G. Intervention Timing and Acute Coronary Syndromes. JAMA. 2010;303(2):131-132. doi:10.1001/jama.2009.1968